v3.26.1
Note 7 - Segment Reporting - Reconciliation of Segment Operations (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
General and administrative $ 1,800,513   $ 2,182,289   $ 3,548,752 $ 3,611,586
Other income 37,290   6,881   69,038 11,652
Net loss (4,447,219) $ (4,461,895) (4,674,901) $ (3,964,601) (8,909,114) (8,639,502)
Operating Segments [Member] | Single Reportable Segment [Member]            
Revenues 0   0   0 0
Clinical and regulatory 1,538,749   1,659,513   3,229,150 3,366,218
Manufacturing 423,306   472,598   1,035,518 955,663
Research 703,221   328,991   1,112,056 637,317
General and administrative 1,750,354   1,761,764   3,414,455 3,048,187
Non-cash expenses(1) [1],[2] 68,354   458,918   186,989 643,690
Realized and unrealized loss 525   0   0 79
Other income 37,290   6,881   69,038 11,652
Realized and unrealized gain 0   2   16 0
Net loss $ (4,447,219)   $ (4,674,901)   $ (8,909,114) $ (8,639,502)
[1] Includes $230,861 and $184,773 of stock-based compensation expense for the three months ended March 31, 2026 and 2025.
[2] Includes $68,354 and $458,918 of stock-based compensation expense for the three months ended June 30, 2026 and 2025, respectively.